BAY-6672
Probe criteria
| Inhibitor/agonist potency: goal is < 50 nM (IC50, KD) | Surpasses criterion: hPTGFR: IC50 = 22 nM (Ki = 16 nM; binding assay, Panlabs) |
| Selectivity within target family: > 30-fold | Surpasses criterion: > 420-fold selectivity vs prostanoids EP1–EP4, IP, DP, CRTH2 based on binding assays (Panlabs); 200-fold vs human TBXA2R (TP, IC50= 2.2 µM) based on cell-based assay (Panlabs); no agonismClean PDSP scan |
| Selectivity outside target family | Panlabs Lead Profiling Screen (77 targets): no off-targets; Ion Channel Profiler: IC20 > 10 μM (8 ion channels) |
| On target cell activity for cell-based targets: goal is < 1 µM IC50/EC50 | Surpasses criterion: hPTGFR: IC50 = 11 nM (cell-based assay, Bayer inhouse); IC50 = 12 nM / 18 nM (functional cell-based assays, cytokine production (KC / MCP-1) in 3T3 fibroblasts); IC50 = 52 nM (functional tissue contraction assay, rat) |
| Control compound (100 times less potent than the probe) | Surpasses criterion: BAY-403: inactive in the hPTGFR binding assay (IC50 > 10 µM) and 100-fold less potent in the hPTGFR cell assay (IC50 = 1.2 µM)Prostaglandin receptor binding (EP1-4, DP1-2, IP): For all IC50 > 10 µM (Panlabs); cell-based human TBXA2R (TP, IP1) assay: IC50 > 10 µM) (Panlabs)Closest off-targets in the PDSP scan are HTR3A (Ki = 584.83 nM) and TMEM97 (Ki = 1099.22 nM). |